5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Glenmark Pharmaceuticals Ltd.

•
glenmarkpharma.comBSE: 532296NSE: GLENMARK
Market Cap₹ 68,211 Cr.
Current Price
High / Low₹ 2,538 / 1,793
Stock P/E333.4
Book Value₹ 882
Price to Book2.49
Dividend Yield0.10 %
ROCE-0.8 %
ROE-0.8 %
Face Value₹ 1

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Latest quarter profit grew 122.8% YoY, showing strong momentum
  • Company generates healthy free cash flow
  • Company has a consistent dividend-paying track record

CONS

  • Company is loss-making at the operating / net level
  • Recent results are weak - TTM profit is down 74.8% versus prior year
  • Receivables are growing faster than sales - a possible quality concern
  • Interest coverage is weak at -2.4x - earnings barely cover interest
  • Poor cash conversion - profits are not backed by operating cash flow (CFO/PAT 0.10x)

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTYM150MOMNTM50NIFTY ALPHA 50NIFTY PHARMANIFTY500MOMENTM50NIFTYLARGEMIDCAP250
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.BIOCON390.95128.6363712.890.13136.8053.364336.0010.893.2619.54
Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
2,0982,1701,3042,0772,2972,5952,2091,9102,1791,2202,3282,2082,435
1,6591,7901,5491,6511,6981,8571,7571,6691,6671,7171,8642,1151,907
Operating Profit439380-245426598737451241512-49746493528
OPM %20.91%17.53%-18.80%20.53%26.05%28.42%20.44%12.62%23.50%-40.76%19.93%4.19%21.67%
18542345,9335683129-91-254-646-68-61-108
Interest6258748315128131523221823
Depreciation49505152535555565859596062
Profit before Tax392389-766,295618795559181401-906347-107866
Tax %30.71%22.35%72.97%26.71%26.62%25.16%26.04%18.44%17.68%18.45%18.60%31.19%15.06%
Net Profit272302-204,614454595414148330-739282-74736
9.6310.72-0.72163.5016.0821.0914.665.2411.70-26.1910.00-2.6226.07

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
8,0966,4326,3056,7137,5688,1428,2217,8919,2268,4408,190
5,1975,1074,9775,4085,6786,4536,7486,6496,9827,3637,603
Operating Profit2,8991,3261,3271,3041,8901,6881,4731,2422,2441,077587
OPM %35.81%20.61%21.05%19.43%24.98%20.74%17.92%15.73%24.32%12.77%7.17%
-881808216254701,0454906,238177-1,029-883
Interest153191224256266236207277497987
Depreciation10596106139151160184202219236241
Profit before Tax2,5531,2191,8181,5351,9442,3371,5727,0012,154-266199
Tax %16.15%16.78%18.14%11.74%15.14%14.53%23.10%26.19%25.24%24.53%-2.89%
Net Profit2,1411,0141,4881,3551,6491,9981,2095,1671,610-201205
EPS75.8435.9557.4948.0058.4670.8042.84183.1157.07-7.12—
Dividend Payout %2.64%5.56%3.79%5.21%4.28%3.53%5.84%1.37%4.38%-35.13%—

COMPOUNDED SALES GROWTH

10 Years:
3%
5 Years:
2%
3 Years:
1%

COMPOUNDED PROFIT GROWTH

10 Years:
—
5 Years:
—
3 Years:
—

STOCK PRICE CAGR

10 Years:
11%
5 Years:
36%
3 Years:
44%
1 Year:
14%

RETURN ON EQUITY

10 Years:
12%
5 Years:
10%
3 Years:
10%
Last Year:
-1%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Corporate actions

2026

Aug 31

₹ 2.50

Rs.2.5000 per share(250%)Final Dividend

2025

Oct 3

₹ 2.50

Interim Dividend

2025

Sep 15

₹ 2.50

Rs.2.5000 per share(250%)Final Dividend

2024

Sep 13

₹ 2.50

Rs.2.5000 per share(250%)Final Dividend

2023

Sep 18

₹ 2.50

Rs.2.5000 per share(250%)Final Dividend

2022

Sep 12

₹ 2.50

Rs.2.5000 per share(250%)Final Dividend

2021

Sep 8

₹ 2.50

Rs.2.5000 per share(250%)Final Dividend

2018

Sep 19

₹ 2

Rs.2.0000 per share(200%)Dividend

2017

Sep 20

₹ 2

Rs.2.0000 per share(200%)Dividend

2016

Aug 3

₹ 2

Rs.2.0000 per share(200%)Dividend

2015

Sep 10

₹ 2

Rs.2.0000 per share(200%)Dividend

2026

Jul 31

₹ 2.50

Rs.2.5000 per share(250%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital28282828282828282828
9,40710,35311,90313,18414,76616,70817,84722,94024,47324,117
2,7792,9843,2233,7793,8183,1053,4176549241,489
Trade Payables1,4671,5551,6681,5851,6231,9392,0932,7002,1822,746
1,643-315-3921,1612,7733,8403,5405,0875,1635,836
Total Liabilities15,32414,60416,43119,73823,00725,61926,92531,41032,77034,216
1,5961,6991,4131,6121,7221,7521,7461,7561,9792,028
Capital Work in Progress2353542091529310115917512167
1,8673,2133,2694,7146,9908,55910,33312,96515,19515,202
1,1451,1119118387629521,0901,1431,3691,288
00000002,4842,5503,306
Cash & Bank25217725688163094129133293
10,2298,05010,37112,33413,42314,22513,50312,75711,42312,032
Total Assets15,32414,60416,43119,73823,00725,61926,92531,41032,77034,216

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
1,5241,4162,8881,9181,5791,6071,890-495589543
Cash from Investing-2,580-1,137-2,256-1,607-1,235-897-4313,197-490569
Cash from Financing1,879-62-155-139-81-305-978-2,666-95-952
177-7579-168-731464354160

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
46.6546.6546.6546.6546.6546.6546.6546.6546.65
20.9823.0523.5123.1520.6220.7319.2020.3520.89
13.9213.2113.8514.6017.6418.6120.0919.2818.60
0.040.040.040.040.040.040.040.040.04
18.4117.0615.9615.5615.0613.9714.0213.6813.81

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-11
Shareholders meeting

2026-09-11 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 11, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.

2026-09-11
Press Release

2026-09-11 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 11, 2026, titled "Glenmark Expands Global Respiratory Innovation Footprint with RYALTRIS® Launch in Brazil ".

2026-09-11
Credit Rating

2026-09-11 - Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating

2026-08-21
Press Release

2026-08-21 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 21, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package".

2026-08-20
Press Release

2026-08-20 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 20, 2026, titled "Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray".

2026-08-15
Copy of Newspaper Publication

2026-08-15 - Glenmark Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-13
General Updates

2026-08-13 - Letter to shareholders whose email address are not registered providing the Web Link of Integrated Annual Report

2026-08-13
Shareholders meeting

2026-08-13 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 11, 2026

2026-08-11
General Updates

2026-08-11 - Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

News

Recent coverage and analyst commentary for GLENMARK

Loading news…

🤖

AI Stock Analyst

Glenmark Pharmaceuticals Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login